OKYO Pharma (OKYO) Insider Trading & Ownership $1.13 +0.07 (+6.60%) Closing price 02/4/2025 04:00 PM EasternExtended Trading$1.10 -0.03 (-3.10%) As of 02/4/2025 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends OKYO Pharma (NASDAQ:OKYO) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage40.46%Number OfInsiders Buying(Last 3 Years)1Amount OfInsider Buying(Last 3 Years)$25,005.00Number OfInsiders Selling(Last 3 Years)0 Get OKYO Insider Trade Alerts Want to know when executives and insiders are buying or selling OKYO Pharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address OKYO Insider Buying and Selling by Quarter OKYO Pharma Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails9/15/2023John P BrancaccioDirectorBuy16,670$1.50$25,005.00 (Data available from 1/1/2013 forward) OKYO Insider Trading Activity - Frequently Asked Questions Who is on OKYO Pharma's Insider Roster? The list of insiders at OKYO Pharma includes John P Brancaccio. Learn more on insiders at OKYO. What percentage of OKYO Pharma stock is owned by insiders? 40.46% of OKYO Pharma stock is owned by insiders. Learn more on OKYO's insider holdings. Which OKYO Pharma insiders have been buying company stock? The following insider purchased OKYO shares in the last 24 months: John P Brancaccio ($25,005.00). How much insider buying is happening at OKYO Pharma? Insiders have purchased a total of 16,670 OKYO shares in the last 24 months for a total of $25,005.00 bought. OKYO Pharma Key ExecutivesDr. Gary S. Jacob Ph.D. (Age 77)CEO & Executive Director Compensation: $650kMr. Michael Paul Beck (Age 67)Founder Ms. Keeren Shah (Age 48)Chief Financial Officer Dr. William A. Clementi Ph.D.Pharm.D., Chief Operating OfficerDr. Rajkumar Patil Ph.D. (Age 65)Chief Scientific Officer More Insider Trading Tools from MarketBeat Related Companies Black Diamond Therapeutics Insider Transactions Genelux Insider Transactions Caribou Biosciences Insider Transactions Coherus BioSciences Insider Transactions TScan Therapeutics Insider Transactions Renovaro Insider Transactions 2seventy bio Insider Transactions Nuvectis Pharma Insider Transactions Cidara Therapeutics Insider Transactions Solid Biosciences Insider Transactions Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles These Are the Dividend Stocks Insiders Bought in JanuaryInsider Selling in Tech Stocks Spikes in Q43 Small-Cap Stocks Insiders and Institutions Are Buying3 Stocks With Strong Capital Returns and Insider Buying SignalsZymeworks in Focus for Insider Activity: Catalysts Ahead This page (NASDAQ:OKYO) was last updated on 2/5/2025 by MarketBeat.com Staff From Our PartnersNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredNew crypto boom will be greatest in historyUrgent Notice from Ian King, the Crypto Expert Who Made 18,325% in a Year: “Donald Trump’s second term is t...Banyan Hill Publishing | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OKYO Pharma Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share OKYO Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
